As of November 4, 2026, Vistagen Therapeutics, Inc. is a publicly traded company (Nasdaq: VTGN); its largest reported holder is Commodore Capital, with 9.9% on Schedule 13G/A of August 14, 2026, then Chen Yu (6.7%). The largest insider holding is Shawn K. Singh, the chief executive and president, with 75,721 shares (0.17% of shares outstanding), per Form 4 of July 2, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Vistagen Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Vistagen Therapeutics, Inc. a real, registered company?
- Vistagen Therapeutics, Inc. files with the SEC under CIK 1411685 (its SEC filings).
- Its shares are listed under the ticker VTGN on Nasdaq (SEC company record).
- Incorporated in Nevada; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under VistaGen Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-04).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-10-30).
- Leadership changes: the latest reported is Angel S. Angelov, Chief Medical Officer (Form 8-K filed 2026-05-19). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Chen Yu (filed 2026-08-14).
Who are Vistagen Therapeutics, Inc.'s owners and officers?
Vistagen Therapeutics, Inc.: incorporated in Nevada; business address in South San Francisco, California; industry Pharmaceutical Preparations (Form 8-K, 2026-10-30).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-02-21)
- : Executive Officer (Form D, 2023-02-21)
- : Director (Form D, 2023-02-21)
- : Director (Form D, 2023-02-21)
- : Director (Form D, 2023-02-21)
- : Director (Form D, 2023-02-21)
- : Director (Form D, 2023-02-21)
- : Director (Form D, 2023-02-21)
- : Executive Officer (Form D, 2023-02-21)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Orbimed Advisors LLC | 0% |
| Schedule 13G/A, 2026-08-14 | Chen Yu | 6.7% |
| Schedule 13G/A, 2026-08-14 | Commodore Capital LP | 9.9% |
| Schedule 13G/A, 2026-05-15 | Chen Yu | 9.99% |
| Schedule 13G/A, 2026-02-17 | Janus Henderson Group PLC | 0% |
| Schedule 13G/A, 2026-02-17 | Orbimed Capital LLC | 4.2% |
| Schedule 13G/A, 2026-02-17 | Stempoint Capital LP | 1.5% |
| Schedule 13G/A, 2026-02-17 | Commodore Capital LP | 9.9% |
| Schedule 13G/A, 2026-02-17 | Great Point Partners, LLC | 4.95% |
| Schedule 13G/A, 2026-02-13 | Nantahala Capital Management, LLC | 4.71% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 4.62% |
| Schedule 13G, 2025-11-14 | Orbimed Capital LLC | 5.34% |
Questions about who owns Vistagen Therapeutics, Inc.
Who owns Vistagen Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Vistagen Therapeutics, Inc.: Commodore Capital LP (9.9%, Schedule 13G/A, filed 2026-08-14) and Chen Yu (6.7%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Vistagen Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Vistagen Therapeutics, Inc. on this page are Commodore Capital LP (9.9%) and Chen Yu (6.7%).
When did Commodore Capital LP buy into Vistagen Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Commodore Capital LP on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.9%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Vistagen Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vistagen Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vistagen Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-05-19 | Angel S. Angelov | Chief Medical Officer | appointed |
Which insiders own Vistagen Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 75,721 shares (0.17% of shares outstanding), 54,846 held directly and 20,875 indirectly (Form 4, 2026-07-02).
- , the chief legal officer: 60,868 shares (0.14% of shares outstanding) (Form 4, 2026-07-02).
- , the chief operating officer: 15,249 shares (0.03% of shares outstanding) (Form 4, 2026-01-05).
- , the chief financial officer: 12,801 shares (0.03% of shares outstanding) (Form 4, 2025-07-01).
- , the chief financial officer: 11,712 shares (0.03% of shares outstanding) (Form 4, 2026-07-02).
Shares outstanding: 44,376,911 as of 2026-08-10, from the company's latest SEC cover page.
How much has Vistagen Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-02-21 | $0 | $2.80M |
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-10-30).
Keep reading
More on Vistagen Therapeutics, Inc. and the records around it.
Vistagen Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Jul 2026
Companies that share a holder
- StemPoint Capital LP also filed stake reports on 4 other companies: Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026)
- TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Abivax SA (Aug 2026), Entrada Therapeutics, Inc. (Aug 2026), Savara Inc. (Feb 2026)
- Great Point Partners, LLC also filed stake reports on 13 other companies: Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026), AMANAT ACQUISITION CORP (Aug 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/vistagen-therapeutics